Vir Biotechnology, Inc. (VIR) shareholders
Close on Nov 17, 2026Market cap $1.57BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 20,905,681 | 12.40% | 13G (passive) amendment | Sep 30, 2026 |
| Robert Nelsen Joint filing with Keith Crandell (7.10%), Clinton Bybee (7.00%) and 5 more | 12,508,029 | 7.30% | 13D (active) amendment | Nov 4, 2026 |
| Vanguard Portfolio Management | 11,554,377 | 6.85% | 13G (passive) amendment | Jun 30, 2026 |
| SoftBank Vision Fund (AIV M1) L.P. Joint filing with SB Investment Advisers (UK) Limited (6.50%), SVF Endurance (Cayman) Limited (6.50%) | 10,948,093 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VIR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,678,283 | 12.22% | $210.71M | +2,679,954 | 0.00% |
| ARCH Venture Management, LLC | 12,694,163 | 7.50% | $129.35M | −222,500 | 11.76% |
| Vanguard Portfolio Management LLC | 11,495,215 | 6.79% | $117.14M | +2,279,638 | 0.01% |
| Sb Investment Advisers (Uk) Ltd | 10,948,093 | 6.47% | $111.56M | – | 1.46% |
| State Street Corp | 9,964,151 | 5.89% | $101.53M | +2,823,057 | 0.00% |
| GSK plc | 8,550,954 | 5.05% | $87.13M | – | 14.47% |
| Vanguard Capital Management LLC | 6,388,775 | 3.78% | $65.10M | +1,006,672 | 0.00% |
| Point72 Asset Management, L.P. | 5,666,821 | 3.35% | $57.74M | +3,714,587 | 0.06% |
| Geode Capital Management, LLC | 3,348,366 | 1.98% | $34.12M | +690,523 | 0.00% |
| Dimensional Fund Advisors LP | 3,119,421 | 1.84% | $31.79M | +539,743 | 0.01% |
| ADAR1 Capital Management, LLC | 2,456,677 | 1.45% | $25.03M | −288,037 | 1.15% |
| Goldman Sachs Group Inc | 2,365,219 | 1.40% | $24.10M | −885,008 | 0.00% |
| FMR LLC | 2,318,294 | 1.37% | $23.62M | +246,446 | 0.00% |
| Morgan Stanley | 2,211,077 | 1.31% | $22.53M | −643,128 | 0.00% |
| Nuveen, LLC | 1,982,942 | 1.17% | $20.21M | +963,978 | 0.00% |
| Pictet Asset Management Holding SA | 1,953,316 | 1.15% | $19.90M | +472,488 | 0.02% |
| Boxer Capital Management, LLC | 1,866,000 | 1.10% | $19.01M | – | 1.43% |
| Northern Trust Corp | 1,432,165 | 0.85% | $14.59M | +446,730 | 0.00% |
| Hudson Bay Capital Management LP | 1,364,000 | 0.81% | $13.90M | −105,510 | 0.04% |
| GordonMD Global Investments LP | 1,353,552 | 0.80% | $13.79M | −165,000 | 6.67% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 237 | 147M | 86.6% | 33 / 93 | 77 / 43 | 22M | 16M |
| Q1 2026 | 252 | 140M | 82.8% | 69 / 118 | 41 / 30 | 52M | 15M |
| Q4 2025 | 218 | 116M | 68.5% | 33 / 66 | 79 / 26 | 19M | 11M |
| Q3 2025 | 213 | 107M | 63.5% | 28 / 60 | 82 / 26 | 6M | 10M |
| Q2 2025 | 213 | 111M | 65.9% | 23 / 82 | 61 / 42 | 24M | 6M |
| Q1 2025 | 233 | 93M | 55.1% | 53 / 74 | 70 / 26 | 15M | 10M |
| Q4 2024 | 208 | 89M | 52.5% | 42 / 68 | 70 / 29 | 12M | 10M |
| Q3 2024 | 197 | 89M | 52.4% | 22 / 77 | 67 / 38 | 23M | 7M |
| Q2 2024 | 215 | 89M | 52.7% | 34 / 74 | 73 / 25 | 10M | 15M |
| Q1 2024 | 209 | 94M | 55.8% | 31 / 72 | 67 / 27 | 10M | 6M |
| Q4 2023 | 206 | 91M | 53.5% | 28 / 68 | 74 / 33 | 11M | 9M |
| Q3 2023 | 214 | 89M | 52.3% | 40 / 96 | 52 / 52 | 15M | 17M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
237 funds held VIR in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VIR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7,317,395 | 4.32% | $74.56M | 0.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,945,485 | 2.92% | $50.39M | 0.47% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,846,948 | 2.86% | $49.39M | 0.00% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,476,669 | 2.05% | $35.43M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,155,076 | 1.86% | $32.15M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,996,625 | 1.18% | $20.35M | 0.04% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 1,762,412 | 1.04% | $17.96M | 0.15% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,398,483 | 0.83% | $14.25M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,343,751 | 0.79% | $11.64M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,150,997 | 0.68% | $11.73M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 1,114,301 | 0.66% | $11.35M | 0.07% | Jun 30, 2026 |
| iShares Biotechnology ETF | 949,158 | 0.56% | $9.67M | 0.11% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 892,320 | 0.53% | $7.73M | 0.19% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 868,792 | 0.51% | $8.85M | 0.28% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 677,373 | 0.40% | $6.90M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Backer Marianne De | President and CEO, Director | 1,001,263 | 0.59% | Apr 30, 2026 |
| Aziz Sawaf | EVP, Chief Financial Officer | 75,000 | 0.04% | Nov 16, 2026 |
| Brent Sabatini | SVP, Chief Accounting Officer | 111,902 | 0.07% | Nov 16, 2026 |
| Verneuil Vanina de | EVP, General Counsel, Corp Sec | 110,193 | 0.07% | Nov 4, 2026 |
| Jason O'Byrne | EVP & Chief Financial Officer | 162,615 | 0.10% | Mar 23, 2026 |
| Mark Eisner | EVP and Chief Medical Officer | 154,024 | 0.09% | Feb 26, 2026 |
| Ann M. Hanly | EVP & Chief Technology Officer | 117,913 | 0.07% | Feb 25, 2025 |
| Suzanne Louise Topalian | Director | 12,731 | 0.01% | Oct 28, 2026 |
| Robert J. More | Director | 558,573 | 0.33% | Aug 12, 2026 |
| Timothy Coughlin | Director | 0 | – | Jun 10, 2026 |
| Janet Napolitano | Director | 21,216 | 0.01% | Jun 2, 2026 |
| Jeffrey S. Hatfield | Director | 39,806 | 0.02% | May 28, 2026 |
| Norbert W. Bischofberger | Director | 32,000 | 0.02% | May 28, 2026 |
| Charles Elliott Sigal | Director | 49,806 | 0.03% | May 28, 2026 |
| Ramy Farid | Director | 32,000 | 0.02% | May 28, 2026 |
| Vicki L. Sato | Director | 1,078,391 | 0.64% | May 4, 2026 |
| Saira Ramasastry | Director | 22,619 | 0.01% | Jun 2, 2025 |
| George A. Scangos | Director | 1,849,969 | 1.09% | Feb 25, 2025 |
| Endurance (Cayman) Ltd SVF | 10% owner | 13,728,924 | 8.11% | Dec 3, 2025 |
| Vision Fund (Aiv M1) L.P. Softbank | 10% owner | 13,920,778 | 8.23% | Dec 3, 2025 |
| Investment Advisers (Uk) Ltd Sb | 10% owner | 14,598,536 | 8.63% | Dec 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Aziz Sawaf EVP, Chief Financial Officer | Nov 15, 2026 | Award | +75,000 | – | – | 75,000 |
| Brent Sabatini SVP, Chief Accounting Officer | Nov 15, 2026 | Award | +50,000 | – | – | 111,902 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Nov 3, 2026 | Sale(10b5-1 plan) | −2,407 | $11.10 | $26.72K | 110,193 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Nov 2, 2026 | Sale(10b5-1 plan) | −1,343 | $11.33 | $15.22K | 112,600 |
| Suzanne Louise Topalian Director | Oct 27, 2026 | Award | +4,731 | – | – | 12,731 |
| Suzanne Louise Topalian Director | Oct 27, 2026 | Award | +8,000 | – | – | 8,000 |
| Robert J. More Director | Aug 11, 2026 | Other | −8,000 | – | – | 40,656 |
| Robert J. More Director | Aug 11, 2026 | Other | +8,000 | – | – | 517,917 |
| Timothy Coughlin Director | Jun 9, 2026 | Award | +8,000 | – | – | 8,000 |
| Timothy Coughlin Director | Jun 9, 2026 | Award | +8,000 | – | – | 16,000 |
| Brent Sabatini SVP, Chief Accounting Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −379 | $9.45 | $3.58K | 61,902 |
| Janet Napolitano Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,200 | $9.45 | $30.24K | 21,216 |
| Jeffrey S. Hatfield Director | May 27, 2026 | Award | +8,000 | – | – | 39,806 |
| Ramy Farid Director | May 27, 2026 | Award | +8,000 | – | – | 32,000 |
| Charles Elliott Sigal Director | May 27, 2026 | Award | +8,000 | – | – | 39,806 |
| Janet Napolitano Director | May 27, 2026 | Award | +8,000 | – | – | 24,416 |
| Robert J. More Director | May 27, 2026 | Award | +8,000 | – | – | 48,656 |
| Norbert W. Bischofberger Director | May 27, 2026 | Award | +8,000 | – | – | 21,333 |
| Vicki L. Sato Director | May 1, 2026 | Sale(10b5-1 plan) | −22,000 | $10.05 | $221.10K | 1,078,391 |
| Backer Marianne De President and CEO, Director | Apr 29, 2026 | Other | +233,532 | – | – | 286,650 |
| Backer Marianne De President and CEO, Director | Apr 29, 2026 | Other | −233,532 | – | – | 714,613 |
| Backer Marianne De President and CEO, Director | Apr 6, 2026 | Sale(10b5-1 plan) | −72,559 | $9.16 | $664.64K | 948,145 |
| Vicki L. Sato Director | Apr 1, 2026 | Sale(10b5-1 plan) | −22,000 | $9.07 | $199.54K | 1,100,391 |
| Brent Sabatini SVP, Chief Accounting Officer | Mar 23, 2026 | Sale(10b5-1 plan) | −7,711 | $9.12 | $70.32K | 61,902 |
| Jason O'Byrne EVP & Chief Financial Officer | Mar 20, 2026 | Other | +2,500 | – | – | 2,500 |
| Jason O'Byrne EVP & Chief Financial Officer | Mar 20, 2026 | Other | −2,500 | – | – | 160,115 |
| Vicki L. Sato Director | Mar 2, 2026 | Sale(10b5-1 plan) | −21,800 | $9.50 | $207.10K | 1,122,591 |
| Vicki L. Sato Director | Mar 2, 2026 | Sale(10b5-1 plan) | −200 | $9.98 | $2.00K | 1,122,391 |
| Mark Eisner EVP and Chief Medical Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −1,889 | $9.82 | $18.55K | 154,024 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 25, 2026 | Sale(10b5-1 plan) | −13,700 | $9.82 | $134.53K | 112,982 |
| Mark Eisner EVP and Chief Medical Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,616 | $9.53 | $15.40K | 155,913 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 24, 2026 | Sale(10b5-1 plan) | −3,117 | $9.53 | $29.71K | 126,682 |
| Jason O'Byrne EVP & Chief Financial Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,634 | $9.53 | $15.57K | 162,615 |
| Backer Marianne De Chief Executive Officer, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −14,762 | $9.53 | $140.68K | 1,020,704 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −1,430 | $9.53 | $13.63K | 69,613 |
| Vicki L. Sato Director | Feb 24, 2026 | Sale(10b5-1 plan) | −200 | $10.26 | $2.05K | 1,144,391 |
| Vicki L. Sato Director | Feb 24, 2026 | Sale(10b5-1 plan) | −42,177 | $9.75 | $411.23K | 1,144,591 |
| Vicki L. Sato Director | Feb 24, 2026 | Option exercise | +42,377 | $1.49 | $63.14K | 1,186,768 |
| Mark Eisner EVP and Chief Medical Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −2,089 | $7.45 | $15.56K | 157,529 |
| Jason O'Byrne EVP & Chief Financial Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −2,089 | $7.45 | $15.56K | 164,249 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −1,829 | $7.45 | $13.63K | 71,043 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 23, 2026 | Sale(10b5-1 plan) | −4,445 | $7.45 | $33.12K | 129,799 |
| Backer Marianne De Chief Executive Officer, Director | Feb 23, 2026 | Sale(10b5-1 plan) | −19,039 | $7.45 | $141.84K | 1,035,466 |
| Mark Eisner EVP and Chief Medical Officer | Feb 22, 2026 | Award | +55,000 | – | – | 159,618 |
| Jason O'Byrne EVP & Chief Financial Officer | Feb 22, 2026 | Award | +55,000 | – | – | 166,338 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 22, 2026 | Award | +25,000 | – | – | 72,872 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Feb 22, 2026 | Award | +55,000 | – | – | 134,244 |
| Backer Marianne De Chief Executive Officer, Director | Feb 22, 2026 | Award | +285,000 | – | – | 1,054,505 |
| Brent Sabatini SVP, Chief Accounting Officer | Feb 13, 2026 | Sale(10b5-1 plan) | −1,530 | $7.79 | $11.92K | 47,872 |
| Vicki L. Sato Director | Feb 2, 2026 | Sale(10b5-1 plan) | −22,000 | $7.71 | $169.62K | 1,144,391 |
| Vicki L. Sato Director | Jan 2, 2026 | Sale(10b5-1 plan) | −22,000 | $5.93 | $130.46K | 1,166,391 |
| Endurance (Cayman) Ltd SVF 10% owner | Dec 1, 2025 | Sale(10b5-1 plan) | −191,854 | $5.98 | $1.15M | 13,728,924 |
| Vicki L. Sato Director | Dec 1, 2025 | Sale(10b5-1 plan) | −22,000 | $6.00 | $132.00K | 1,188,391 |
| Vision Fund (Aiv M1) L.P. Softbank 10% owner | Nov 28, 2025 | Sale(10b5-1 plan) | −61,493 | $6.44 | $396.01K | 13,920,778 |
| Vision Fund (Aiv M1) L.P. Softbank 10% owner | Nov 26, 2025 | Sale(10b5-1 plan) | −127,938 | $6.39 | $817.52K | 13,982,271 |
| Endurance (Cayman) Ltd SVF 10% owner | Nov 25, 2025 | Sale(10b5-1 plan) | −235,971 | $6.38 | $1.51M | 14,110,209 |
| Endurance (Cayman) Ltd SVF 10% owner | Nov 24, 2025 | Sale(10b5-1 plan) | −227,803 | $6.15 | $1.40M | 14,346,180 |
| Jason O'Byrne EVP & Chief Financial Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −6,799 | $5.56 | $37.80K | 110,701 |
| Verneuil Vanina de EVP, General Counsel, Corp Sec | Nov 5, 2025 | Sale(10b5-1 plan) | −2,385 | $5.16 | $12.31K | 78,210 |
| Vicki L. Sato Director | Nov 3, 2025 | Sale(10b5-1 plan) | −22,000 | $5.64 | $124.08K | 1,210,391 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vir Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 84,198 shares on Oct 6, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Verneuil Vanina de Officer | Nov 3, 2026 | 2,407 | $26.72K | Nov 3, 2026 | Restricted Stock Vesting |
| Verneuil Vanina de Officer | Nov 2, 2026 | 1,343 | $15.22K | Nov 2, 2026 | Restricted Stock Vesting |
| Jason O'Byrne Former Officer | Sep 17, 2026 | 19,357 | $212.93K | Sep 17, 2026 | Restricted Stock Vesting |
| Jason O'Byrne Former Officer | Sep 9, 2026 | 28,333 | $315.24K | Sep 9, 2026 | Stock Option Exercise |
| Jason O'Byrne Former Officer | Aug 25, 2026 | 23,148 | $242.59K | Aug 25, 2026 | Stock Option Exercise |
| Jason O'Byrne Former Officer | Aug 24, 2026 | 14,352 | $142.12K | Aug 24, 2026 | Stock Option Exercise |
| Jason O'Byrne Former Officer | Aug 21, 2026 | 25,000 | $245.30K | Aug 21, 2026 | Stock Option Exercise |
| Saira Ramasastry Former Director | Jun 29, 2026 | 16,000 | $165.14K | Jun 29, 2026 | Stock Option Exercise |
| Janet Napolitano Director | Jun 1, 2026 | 3,200 | $30.24K | Jun 1, 2026 | Restricted Stock Vesting |
| Brent Sabatini Officer | Jun 1, 2026 | 379 | $3.58K | Jun 1, 2026 | ESPP Purchase |
| Mark Eisner Former Officer | Apr 30, 2026 | 88,958 | $916.27K | Apr 30, 2026 | Option Granted - 07/15/2024 |
| Backer Marianne De Officer, Director | Apr 6, 2026 | 72,559 | $664.34K | Apr 6, 2026 | Restricted Stock Vesting |
| Brent Sabatini Officer | Mar 23, 2026 | 7,711 | $70.32K | Mar 23, 2026 | Restricted Stock Vesting |
| Vicki L. Sato Director | Mar 2, 2026 | 88,000 | $799.92K | Mar 2, 2026 | Pre-IPO Shares |
| Mark Eisner Officer | Feb 25, 2026 | 1,889 | $18.55K | Feb 25, 2026 | Restricted Stock Vesting |
See a number that looks wrong?